References
- Ursic-Vrscaj M, Rakar S, Možina A, Kobal B, Takač I, Deisinger I, et al. [Guidelines for management of women with cervical precancerous lesions]. [Slovenian] In: Ursic-Vrscaj M, editor. Ljubljana: Institute of Oncology Ljubljana; 2011. [cited 2025 Feb 27]. Available at: https://zora.onko-i.si/file-admin/user_upload/dokumenti/strokovna_priporocila/2011_Smernice_web.pdf
- Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 2012; 136: 1266-97. doi: 10.5858/arpa.LGT200570
- Klavs I, Učakar V, Oštrbenk A, Jelen M, Poljak M. Prevalenca okužb s človeškimi papilomavirusi (HPV) pri ženskah sodelujočih v Državnem pro-gramu zgodnjega odkrivanja predrakavih sprememb materničnega vratu v Sloveniji. In: Ivanuš U, Primic-Žakelj M, editor. Izobraževalni dan Zora, Zbornik predavanj. Ljubljana: Onkološki inštitut; 2014. p. 12-21.
- Fröberg M, Östensson E, Belkić K, Oštrbenk A, Poljak M, Mints M, et al. Impact of the human papillomavirus status on the development of highgrade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study. Cancer 2019; 125: 239-48. doi: 10.1002/cncr.31788
- Gutnik H, Kastelic P, Oštrbenk Valenčak A, Poljak M, Strojan Fležar M. Histomorphologic assessment and distribution of high-risk human papillomavirus (HPV) types in cervical high-grade squamous intraepithelial lesions with unusual histomorphologic features. Virchows Arch 2020; 476: 251-60. doi: 10.1007/s00428-019-02694-7
- WHO Classification of Tumours Editorial Board. Female genital tumours. Lyon: International Agency for Research on Cancer; 2020.
- Miralpeix E, Genovés J, Solé-Sedeño JM, Mancebo G, Lloveras B, Bellosillo B et al. Usefulness of p16INK4a staining for managing histological high-grade squamous intraepithelial cervical lesions. Mod Pathol 2017; 30: 304-10. doi: 10.1038/modpathol.2016.168
- Zhang X, Xu Y, Meng T, Shen D. Analysis of factors affecting the prognosis of patients with cervical intraepithelial neoplasia 2. Oncol Lett 2020; 20: 1810-6. doi: 10.3892/ol.2020.11711
- Maniar KP, Sanchez B, Paintal A, Gursel DB, Nayar R. Role of the Biomarker p16 in Downgrading CIN 2 Diagnoses and Predicting Higher-grade Lesions. Am J Surg Pathol 2015; 39: 1708-18. doi: 10.1097/PAS.0000000000000530
- Ebisch RMF, Rijstenberg LL, Soltani GG, van der Horst J., Vedder J. E., Hermsen M et al. Adjunctive use of p16 immunohistochemistry for optimizing management of CIN lesions in a high-risk human papillomavirus-positive population. Acta Obstet Gynecol Scand 2022; 101:1328-36. doi: 10.1111/aogs.14459
- Liu Y, Alqatari M, Sultan K, Ye F, Gao D, Sigel K, et al. Using p16 immunohistochemistry to classify morphologic cervical intraepithelial neoplasia 2: correlation of ambiguous staining patterns with HPV subtypes and clinical outcome. Hum Pathol 2017; 66: 144-51. doi: 10.1016/j.humpath.2017.06.002
- Sun L, Zhang L, Krigman HR, Hagemann IS. p16 Immunohistochemistry is not always required for accurate diagnosis of grade 2 squamous intraepithelial lesions. J Low Genit Tract Dis 2018; 22: 104-9. doi: 10.1097/LGT.0000000000000370
- Guedes AC, Brenna SM, Coelho SA, Martinez EZ, Syrjänen KJ, Zeferino LC. p16(INK4a) Expression does not predict the outcome of cervical intraepithelial neoplasia grade 2. Int J Gynecol Cancer 2007; 17: 1099-103. doi: 10.1111/j.1525-1438.2007.00899.x
- Loopik DL, Doucette S, Bekkers RLM, Bentley JR. Regression and progression predictors of CIN2 in women younger than 25 years. J Low Genit Tract Dis 2016; 20: 213-7. doi: 10.1097/LGT.0000000000000218
- Cokan A, Pakiž M, Serdinšek T, Dovnik A, Kodrič T, Repše Fokter A, et al. Comparison of conservative treatment of cervical intraepithelial lesions with imiquimod with standard excisional technique using LLETZ: A randomized controlled trial. J Clin Med 2021; 10: 5777. doi: 10.3390/jcm10245777
- Hosseini MS, Talayeh M, Afshar Moghaddam N, Arab M, Farzaneh F, Ashrafganjoei T. Comparison of Ki67 index and P16 expression in different grades of cervical squamous intraepithelial lesions. Caspian J Intern Med 2023; 14: 69-75. doi: 10.22088/cjim.14.1.69
- Liu J, Su S, Liu Y. The value of Ki67 for the diagnosis of LSIL and the problems of p16 in the diagnosis of HSIL. Sci Rep 2022; 12: 7613. doi: 10.1038/s41598-022-11584-z.
- Yajid AI, Zakariah MA, Mat Zin AA, Othman NH. Potential Role of E4 Protein in Human Papillomavirus Screening: a Review. Asian Pac J Cancer Prev 2017; 18: 315-319. doi: 10.22034/APJCP.2017.18.2.315.
- Doorbar J. The E4 protein; structure, function and patterns of expression. Virology 2013; 445: 80–98. doi: 10.1016/j.virol.2013.07.008.
- Hendawi N, Niklander S, Allsobrook O, Khurram SA, Bolt R, Doorbar J, et al. Human papillomavirus (HPV) can establish productive infection in dysplastic oral mucosa, but HPV status is poorly predicted by histological features and p16 expression. Histopathology 2020; 76: 592-602. doi: 10.1111/his.14019
- Leeman A, Jenkins D, Marra E, van Zummeren M, Pirog EC, van de Sandt MM, van Eeden A, Schim van der Loeff MF, Doorbar J, de Vries HJC, van Kemenade FJ, Meijer CJLM, Quint WGV. Grading immunohistochemical markers p16INK4a and HPV E4 identifies productive and transforming lesions caused by low-and high-risk HPV within high-grade anal squamous intraepithelial lesions. Br J Dermatol 2020; 182: 1026-1033. doi: 10.1111/bjd.18342
- Zummeren MV, Kremer WW, Leeman A, Bleeker MCG, Jenkins D, Sandt MV, et al. HPV E4 expression and DNA hypermethylation of CADM1, MAL, and miR124-2 genes in cervical cancer and precursor lesions. Mod Pathol 2018; 31: 1842-1850.
- Leeman A, Jenkins D, Del Pino M, Ordi J, Torné A, Doorbar J, Meijer CJLM, van Kemenade FJ, Quint WGV. Expression of p16 and HPV E4 on biopsy samples and methylation of FAM19A4 and miR124-2 on cervical cytology samples in the classification of cervical squamous intraepithelial lesions. Cancer Med 2020; 9: 2454-2461. doi: 10.1002/cam4.2855.
- Doorbar J, Ely S, Sterling J, McLean C, Crawford L. Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature 1991; 352: 824–827.
- Damgaard RK, Jenkins D, de Koning MN, Quint WG, Stoler MH, Doorbar J, et al. Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study. BMJ Open 2022; 12: e059593. doi: 10.1136/bmjopen-2021-059593
- Van Baars R, Griffin H, Wu Z, et al Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with p16INK4a. Am J Surg Pathol 2015; 39: 1518–28. doi:10.1097/PAS.0000000000000498pmid:http://www.ncbi.nlm.nih.gov/pubmed/26379150
- Griffin H, Soneji Y, Van Baars R, et al. Stratification of HPV-induced cervical pathology using the virally encoded molecular marker E4 in combination with p16 or MCM. Mod Pathol 2015; 28: 977-93. doi:10.1038/modpathol.2015.52 pmid:http://www.ncbi.nlm.nih.gov/pubmed/2595339
- Vink FJ, Dick S, Heideman DAM, De Strooper LM., Steenbergen RD, Lissenberg-Witte BI, et al. Classification of high-grade cervical intraepithelial neoplasia by p16INK4a, Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management. Int J Cancer 2021; 149: 707–16. doi: 10.1002/ijc.33566
- Rodrigo JP, Villaronga MÁ, Menéndez ST, Hermida-Prado F, Quer M, Vilaseca I, et al. A novel role for Nanog as an early cancer risk marker in patients with laryngeal precancerous lesions. Sci Rep 2017; 7: 11110. doi: 10.1038/s41598-017-11709-9
- Grubelnik G, Boštjančič E, Pavlič A, Kos M, Zidar N. NANOG expression in human development and cancerogenesis. Exp Biol Med 2020; 245: 456-64. doi: 10.1177/1535370220905560
- Hu J, Liu J, Chen A, Lyu J, Ai G, Zeng Q, et al. INO80 promotes cervical cancer tumorigenesis by activating Nanog expression. Oncotarget. 2016; 7: 72250-62. doi: 10.18632/oncotarget.12667.
- Javed S, Sood S, Rai B, Bhattacharyya S, Bagga R, Srinivasan R. ALDH1 and CD133 in invasive cervical carcinoma and their association with the outcome of chemoradiation therapy. Indian J Med Res 2021; 154: 367-74. doi: 10.4103/ijmr.IJMR_709_20
- Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 2008; 8: 108. doi: 10.1186/1471-2407-8-108
- Tulake W, Yuemaier R, Sheng L, Ru M, Lidifu D, Abudula A. Upregulation of stem cell markers ALDH1A1 and OCT4 as potential biomarkers for the early detection of cervical carcinoma. Oncol Lett 2018; 16: 5525-34. doi: 10.3892/ol.2018.9381
- Han GH, Kim J, Yun H, Cho H, Chung J, Kim JH, et al. CRY1 regulates chemoresistance in association with NANOG by inhibiting apoptosis via STAT3 pathway in patients with cervical cancer. Cancer Genomics Proteomics 2021; 18: 699-713. doi: 10.21873/cgp.2029
- Díaz-Tejeda Y, Guido-Jiménez MC, López-Carbajal H, Amador-Molina A, Méndez-Martínez R, Gariglio-Vidal P, et al. Nanog, in cooperation with AP1, increases the expression of E6/E7 oncogenes from HPV types 16/18. Viruses 2021; 13: 1482. doi: 10.3390/v13081482
- Organista-Nava J, Gómez-Gómez Y, Ocadiz-Delgado R, García-Villa E, Bonilla-Delgado J, Lagunas-Martínez A, et al. The HPV16 E7 oncoprotein increases the expression of Oct3/4 and stemness-related genes and augments cell self-renewal. Virology 2016; 499: 230-42. doi: 10.1016/j.virol.2016.09.020
- Li X, Wu X, Li Y, Cui Y, Tian R, Singh N, et al. Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo. Oncol Rep 2019; 41: 2351-60. doi: 10.3892/or.2019.6993
- Xu S, Dong Y, Huo Z, Yu L, Xue J, Wang G, et al. SOX11: a potentially useful marker in surgical pathology: a systematic analysis of SOX11 expression in epithelial and non-epithelial tumours. Histopathology 2019; 74: 391-405. doi: 10.1111/his.13757
- Sun Q, Du J, Dong J, Pan S, Jin H, Han X, et al. Systematic investigation of the multifaceted role of SOX11 in cancer. Cancers 2022; 14: 6103. doi: 10.3390/cancers14246103
- International Agency for Research on Cancer (IARC). Cervical cancer screening. IARC Handbooks of Cancer Prevention. 2022; 18: 1-456.
- van Zummeren M, Leeman A, Kremer WW, Bleeker MC., Jenkins D, van de Sandt M, et al. Three-tiered score for Ki-67 and p16INK4a improves accuracy and reproducibility of grading CIN lesions. J Clin Pathol 2018; 71: 981-8. doi: 10.1136/jclinpath-2018-205271
- Grubelnik G, Boštjančič E, Grošelj A, Zidar N. Expression of NANOG and its regulation in oral squamous cell carcinoma. Biomed Res Int 2020; 2020: 8573793. doi: 10.1155/2020/8573793
- Gu TT, Liu SY, Zheng PS. Cytoplasmic NANOG-positive stromal cells promote human cervical cancer progression. Am J Pathol 2012; 181: 652-61. doi: 10.1016/j.ajpath.2012.04.008
- ZORA. Slovenian National Cervical Cancer Screening Programme and Registry. Institute of Oncology Ljubljana. [Internet].2005. [cited 2024 Dec 19]. Available at: https://zora.onko-i.si/en
- Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez-Martinez NE, Torres SM, et al. Relationships of p16 immunohistochemistry and other biomarkers with diagnoses of cervical abnormalities: implications for LAST terminology. Arch Pathol Lab Med 2020; 144: 725-34. doi: 10.5858/arpa.2019-0241-OA
- Petry KU, Cox JT, Johnson K, Quint W, Ridder R, Sideri M, et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer 2016; 138: 2932-9. doi: 10.1002/ijc.30032
- Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human papillomavirus-negative cervical cancer: a comprehensive review. Front Oncol 2021; 10: 606335. doi: 10.3389/fonc.2020.606335
- Vink FJ, Dick S, Heideman DAM, De Strooper LMA, Steenbergen RDM, Lissenberg-Witte BI, et al. Classification of high-grade cervical intraepithelial neoplasia by p16INK4a, Ki-67, HPV E4 and FAM19A4/miR124-2 methylation status demonstrates considerable heterogeneity with potential consequences for management. Int J Cancer 2021; 149: 707-16. doi: 10.1002/ijc.33566
- Kruse AJ, Baak JP, Janssen EA, Kjellevold KH, Fiane B, Lovslett K, et al. Ki67 predicts progression in early CIN: validation of a multivariate progressionrisk model. Cell Oncol 2004; 26: 13-20. doi: 10.1155/2004/108305